MARKET

PTE

PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8678
+0.0572
+7.06%
After Hours: 0.8669 -0.0009 -0.10% 16:32 07/28 EDT
OPEN
0.8501
PREV CLOSE
0.8106
HIGH
0.8797
LOW
0.8243
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
1.990
52 WEEK LOW
0.5530
MARKET CAP
69.97M
P/E (TTM)
-0.8991
1D
5D
1M
3M
1Y
5Y
PolarityTE's SkinTE Meets Primary, Secondary Endpoint Goals In Diabetic Foot Ulcer Trial
PolarityTE Inc (NASDAQ: PTE) 
Benzinga · 6h ago
PolarityTE Sees Positive Data From Trial for Diabetic Foot Ulcer Treatment
marketwatch.com · 8h ago
BRIEF-PolarityTE Says SkinTE Met Primary And Secondary Endpoints In Final Analysis
reuters.com · 9h ago
SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial
SALT LAKE CITY, July 28, 2021--PolarityTE, Inc. (Nasdaq: PTE) today announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its investigational product SkinTE® plus standard of care (SOC)...
Business Wire · 9h ago
BRIEF-PolarityTE Submits IND Application For SkinTE In Chronic Cutaneous Ulcers
reuters.com · 2d ago
PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers
SALT LAKE CITY, July 26, 2021--PolarityTE, Inc. (Nasdaq: PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to eval...
Business Wire · 2d ago
PolarityTE Issues Statement About Potential Ticker Symbol Confusion
PolarityTE, Inc. (NASDAQ:PTE) is issuing the following statement:
Benzinga · 07/16 14:56
PolarityTE secures new Chinese patent; shares up 6%
PolarityTE (PTE) perks up 6% premarket after announcing that the China National Intellectual Property Administration has issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3.The allowed claims relate to skin-regenerative
Seekingalpha · 07/12 12:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTE. Analyze the recent business situations of PolarityTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTE stock price target is 2.750 with a high estimate of 3.000 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 114
Institutional Holdings: 13.55M
% Owned: 16.81%
Shares Outstanding: 80.63M
TypeInstitutionsShares
Increased
16
4.83M
New
11
281.02K
Decreased
7
685.29K
Sold Out
7
2.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.64%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Non-Executive Chairman/Independent Director
Peter Cohen
President/Chief Operating Officer
Richard Hague
Chief Executive Officer
David Seaburg
Chief Financial Officer
Jacob Patterson
Executive Vice President/General Counsel/Secretary
Cameron Hoyler
Independent Director
Minnie Baylor-Henry
Independent Director
Willie Bogan
Independent Director
Jeff Dyer
Independent Director
Chris Nolet
Independent Director
Jessica Shen
Declaration Date
Dividend Per Share
Ex-Div Date
01/04/2016
Dividend USD 0.33550232
01/19/2016
About PTE
PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company's PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.